A New Year, but the Same Old Stock Market
The new year was to have brought a new beginning for China's stock market. Instead, investors who were set to welcome the return of IPO action after a suspension of 14 months were disappointed by news on January 10 that Jiangsu Aosaikang Pharmaceutical Co. Ltd. was putting its anticipated initial public offering on hold.
The abrupt postponement has sparked questions about the regulator's reform agenda. Clearly, at a time when it is trying to clarify its own role vis-à-vis the market, the regulator has yet to master the art of timing. Xiao Gang, chairman of the China Securities Regulatory Commission, said at a work conference this month that reform will see a complete overhaul of the regulator's scope of oversight of the capital market. Its recent actions must be seen in light of this pledge.
- CIC Announces Appointment of Shanghai Vice Mayor as General Manager
- Maiden Flight
- China's Bullet Train Export Hopes Hit a Wall
- Forex Woes Force Qihoo to Extend Privatization Deadline
- Shanghai Cracks Down on Illegal Capital Flight
- Unseen Opportunities Created by 'Brexit'
- Points to Ponder when Building China's Future Megalopolis
- Closer Look: Putin's Latest State Visit Highlights Mutual Interests with China
- Shenzhen Bourse Queries Vanke's Hostile Suitors
- Toxin Fears Trigger School Running Track Furor
- Sign up to receive our free daily newsletter
- Brexit: The View from China
- China Seeks Assurances Against Possible Debt Default by Venezuela
- Senior Ideologue Kills Self over Party Infighting
- Sexually Abused Teens: China's Tragic Taboo
- Chinese High Speed Rail Builder Doubts U.S. Partner's Sincerity
- Substandard Running Tracks Sicken China's Children
- Lessons from South Korea for China's Economic Rebalancing Act
- Investor Pain over Mobile Medical App Strain
- Intensifying Battle over Who Controls Vanke
- Digging Up Death, Extortion in China's Mines